Abstract Few young people with type 1 diabetes (T1D) meet glucose targets. Continuous glucose monitoring improves glycemia, but access is not

of both real-time information that can guide monitoring and management of glycemia and continuous

accumulation in primary human beta cells. Finally, the 5-HT 1F antagonist improved glycemia in marginal

groups using mixed-effects models at 6, 8, 10, and 12 years. Correlations with glycemia were performed.RESULTS: Total